JP2022537159A5 - - Google Patents

Info

Publication number
JP2022537159A5
JP2022537159A5 JP2021573844A JP2021573844A JP2022537159A5 JP 2022537159 A5 JP2022537159 A5 JP 2022537159A5 JP 2021573844 A JP2021573844 A JP 2021573844A JP 2021573844 A JP2021573844 A JP 2021573844A JP 2022537159 A5 JP2022537159 A5 JP 2022537159A5
Authority
JP
Japan
Prior art keywords
item
seq
cd79a
fusion polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573844A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649258B2 (ja
JP2022537159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037145 external-priority patent/WO2020252110A1/en
Publication of JP2022537159A publication Critical patent/JP2022537159A/ja
Publication of JP2022537159A5 publication Critical patent/JP2022537159A5/ja
Application granted granted Critical
Publication of JP7649258B2 publication Critical patent/JP7649258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573844A 2019-06-14 2020-06-11 癌を治療するための組成物および方法 Active JP7649258B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861838P 2019-06-14 2019-06-14
US62/861,838 2019-06-14
US202062991314P 2020-03-18 2020-03-18
US62/991,314 2020-03-18
PCT/US2020/037145 WO2020252110A1 (en) 2019-06-14 2020-06-11 Compositions and methods for treating cancer

Publications (3)

Publication Number Publication Date
JP2022537159A JP2022537159A (ja) 2022-08-24
JP2022537159A5 true JP2022537159A5 (cg-RX-API-DMAC7.html) 2023-06-16
JP7649258B2 JP7649258B2 (ja) 2025-03-19

Family

ID=73780846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573844A Active JP7649258B2 (ja) 2019-06-14 2020-06-11 癌を治療するための組成物および方法

Country Status (12)

Country Link
US (1) US20220280567A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983445A4 (cg-RX-API-DMAC7.html)
JP (1) JP7649258B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220033485A (cg-RX-API-DMAC7.html)
CN (1) CN114206936B (cg-RX-API-DMAC7.html)
AU (1) AU2020291922A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025259A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143248A1 (cg-RX-API-DMAC7.html)
IL (1) IL288914A (cg-RX-API-DMAC7.html)
MA (1) MA56212A (cg-RX-API-DMAC7.html)
MX (1) MX2021015495A (cg-RX-API-DMAC7.html)
WO (1) WO2020252110A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112368021B (zh) * 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体
EP4136119A4 (en) * 2020-04-17 2024-09-11 Regeneron Pharmaceuticals, Inc. MODIFIED CCR POLYPEPTIDES AND USES THEREOF
WO2022140150A1 (en) * 2020-12-21 2022-06-30 2Seventy Bio, Inc. Compositions and methods for site-directed mutagenesis
EP4277904A1 (en) 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
MX2023009113A (es) 2021-02-03 2023-08-10 Seagen Inc Conjugados y compuestos inmunoestimulantes.
AU2022263418A1 (en) * 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024531910A (ja) * 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト Lat活性化キメラ抗原受容体t細胞及びその使用方法
US20230346836A1 (en) * 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
SG11201608701QA (en) * 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015164759A2 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
AU2017235657B2 (en) * 2016-03-18 2022-07-21 Fred Hutchinson Cancer Center Compositions and methods for CD20 immunotherapy
CN105949317B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
JP7467117B2 (ja) * 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
IL270776B2 (en) * 2017-05-25 2024-11-01 Bluebird Bio Inc Cblb endonuclease variants, compositions, and methods of use
MA51428A (fr) * 2017-12-22 2020-11-04 Bluebird Bio Inc Récepteur d'antigène chimérique multivalent
CN112368021B (zh) * 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体

Similar Documents

Publication Publication Date Title
US11932873B2 (en) Reducing immune tolerance induced by PD-L1
TWI771677B (zh) 靶向bcma的工程化免疫細胞及其用途
JP7629414B2 (ja) 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
CN113784733B (zh) 靶向bcma的工程化免疫细胞及其用途
JP2023522038A5 (cg-RX-API-DMAC7.html)
JP2021527409A5 (cg-RX-API-DMAC7.html)
JP2023539591A5 (cg-RX-API-DMAC7.html)
Pircher et al. T cell engineering
US20240335538A1 (en) Novel chimeric antigen receptor and immune cells expressing same
TW202144434A (zh) 人源化cd19抗體及其應用
CN110540997A (zh) 靶向bcma嵌合抗原受体、核酸序列、载体及应用
WO2024115077A1 (en) Cd229 and bcma targeting moieties for the treatment of cd229- bcma- positive cancer
LT7127B (lt) Į bcma nukreipta car-t ląstelių terapija dauginei mielomai gydyti
KR102532260B1 (ko) 돌연변이 EGFR 및 EphA2를 동시 타겟하는 키메라 항원 수용체
Burns The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms)
HK40110123A (en) Engineered immune cell targeting bcma and use thereof
Thomas Updates in Adult Acute Lymphoblastic Leukemia—Current Status of Antigen-targeted Treatments and Immunotherapy
WO2025233431A1 (en) Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
CN120005830A (zh) 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用
HK40062446B (en) Engineered immune cell targeting bcma and use thereof
HK1228783A1 (en) Reducing immune tolerance induced by pd l1
HK1228783B (en) Reducing immune tolerance induced by pd l1
RU2019113504A (ru) Химерные антигенные рецепторы для лечения рака